Secondary endpoints: details revised at 1 of 38 entries
Eligibility criteria expanded, about 5 words
MinorStudy sites: 171 to 169v12
MinorStudy sites: 170 to 171v11
MinorTrial status changed: Recruiting → Active, Not Recruiting
Enrollment target: estimated 3501 to confirmed 3578
Study sites: 171 to 170
v10
MinorStudy sites: 170 to 171v9
MinorTrial sites reduced: 195 → 170 locationsv8
NotableSponsor changed: Metsera, a wholly owned subsidiary of Pfizer to Pfizerv7
MinorEnrollment target: 3500 to 3501v6Show 5 more changesShow less
Study sites: 196 to 195
Primary completion date: Sep 2027 to Sep 21, 2027
Study completion date: May 2028 to Apr 25, 2028
Start date: Dec 29, 2025 to Dec 19, 2025
Secondary endpoints: 9 to 38
MinorTrial sites expanded: 5 → 196 locationsv5
Minor2 versionsRe-verified since Jan 30, 2026, no change to tracked fieldsv3-v4
MinorSite contacts updated at 5 of 5 sitesv2
MinorStudy First Submitted
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks of treatment with the secondary at 84 weeks.